Regeneron Pharmaceuticals (NASDAQ:REGN) Now Covered by Canaccord Genuity Group

Canaccord Genuity Group started coverage on shares of Regeneron Pharmaceuticals (NASDAQ:REGN) in a research report report published on Tuesday morning,Benzinga reports. The firm issued a hold rating and a $165.00 price objective on the biopharmaceutical company’s stock.

A number of other equities research analysts also recently commented on the stock. BMO Capital Markets reduced their price objective on shares of Regeneron Pharmaceuticals from $1,300.00 to $1,190.00 and set an “outperform” rating for the company in a research report on Friday, November 1st. Wolfe Research started coverage on Regeneron Pharmaceuticals in a research note on Friday, November 15th. They issued an “outperform” rating and a $1,150.00 price target on the stock. Evercore ISI dropped their price objective on Regeneron Pharmaceuticals from $1,250.00 to $1,175.00 and set an “outperform” rating on the stock in a report on Thursday, October 24th. Citigroup began coverage on Regeneron Pharmaceuticals in a report on Thursday, November 14th. They issued a “neutral” rating and a $895.00 target price for the company. Finally, StockNews.com cut shares of Regeneron Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research note on Monday, November 4th. One research analyst has rated the stock with a sell rating, five have issued a hold rating, sixteen have given a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $1,052.90.

Regeneron Pharmaceuticals Stock Performance

Shares of REGN stock opened at $740.01 on Tuesday. The stock’s 50-day moving average price is $839.04 and its 200 day moving average price is $1,000.86. The company has a quick ratio of 4.46, a current ratio of 5.28 and a debt-to-equity ratio of 0.09. The stock has a market capitalization of $81.32 billion, a PE ratio of 18.31, a price-to-earnings-growth ratio of 2.19 and a beta of 0.08. Regeneron Pharmaceuticals has a 52-week low of $721.08 and a 52-week high of $1,211.20.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Sachetta LLC raised its holdings in shares of Regeneron Pharmaceuticals by 71.4% in the second quarter. Sachetta LLC now owns 24 shares of the biopharmaceutical company’s stock valued at $26,000 after buying an additional 10 shares during the last quarter. Rakuten Securities Inc. increased its position in Regeneron Pharmaceuticals by 380.0% in the 3rd quarter. Rakuten Securities Inc. now owns 24 shares of the biopharmaceutical company’s stock valued at $25,000 after acquiring an additional 19 shares in the last quarter. Stephens Consulting LLC bought a new position in shares of Regeneron Pharmaceuticals in the second quarter worth about $26,000. FSA Wealth Management LLC acquired a new position in shares of Regeneron Pharmaceuticals during the third quarter worth approximately $26,000. Finally, Family Firm Inc. bought a new stake in shares of Regeneron Pharmaceuticals during the second quarter valued at approximately $33,000. 83.31% of the stock is owned by institutional investors.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.